Glenmark Pharmaceuticals Ltd.
NSE: GLENMARKGlenmark Pharmaceuticals Ltd.: A 30-second snapshot
Glenmark Pharmaceuticals trades at ₹2,340.6, up 69.8% over the past year and 5.4% below its 52-week high, with RSI at 55 (neutral). The stock sits above both the 50-DMA (₹2,226) and 200-DMA (₹2,041). A trailing PE of 61.7 and a forward PE of 29.1 reflect market pricing of earnings improvement, while a debt-to-equity of 12.78 and a profit margin of 6.45% remain notable structural metrics.
P/E
61.7
Forward P/E
29.1
ROE
—
Debt / Equity
12.78
Profit Margin
+6.5%
Div. Yield
+0.2%
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
41/100
News
6 headlines · 3 positive · 1 negative
Glenmark Pharmaceuticals Ltd slips for fifth straight session - Business Standard
Business Standard
Stocks to buy for short term: From Glenmark Pharma to Marico - Ajit Mishra of Religare Broking suggests 3 stock picks - Mint
Mint
Jio Financial, Glenmark Pharma, Marico: Stocks to buy— check price target, stop loss & more - Business Today
Business Today
Trade Spotlight: How should you trade Zydus Lifesciences, Anthem Biosciences, SRF, Solar Industries,... - Moneycontrol.com
Moneycontrol.com
Stock of the day : Glenmark Pharmaceuticals Ltd by Target Rs. 2410 - Religare Broking Ltd - Investment Guru
Investment Guru
Recent context
- ·Business Standard reported five consecutive sessions of price decline as of 12 May 2026, contrasting with the stock's 69.8% gain over the full prior year.
- ·Religare Broking and Business Today named GLENMARK among short-term stock picks in late April 2026; these are third-party views and not a reflection of VivaTrades analysis.
- ·News flow over the tracked window is sparse at 6 total articles (3 positive, 2 neutral, 1 negative), limiting the representativeness of any sentiment reading.
Strengths
- +5-year revenue and earnings growth of 15.1% and 15.8% respectively, indicating consistent top-line and bottom-line expansion over the medium term.
- +Debt trend is classified as falling, suggesting the elevated D/E ratio of 12.78 may be on a downward trajectory from a higher base.
- +Price is above both the 50-DMA (₹2,226) and 200-DMA (₹2,041), with a 52-week drawdown of only 5.4%, reflecting relative price resilience near recent highs.
- +Forward PE of 29.1 represents a meaningful compression from the trailing PE of 61.7, implying analyst consensus anticipates significant earnings improvement in the near term.
Weaknesses
- −Debt-to-equity of 12.78 is substantially above sector peers — Cipla and Dr. Reddys both report D/E well below 1.0 — representing a material structural leverage differential.
- −ROE was above 15% in 0 of the tracked years, and the persistence consistency score of 20 out of 100 reflects weak capital efficiency across the measurement window.
- −Free cash flow was positive in only 2 of the tracked years, indicating the business has predominantly consumed cash despite medium-term earnings growth.
- −Quality score of 41 ranks 4th of 6 sector peers, and trailing PE of 61.7 also ranks 4th of 6, placing GLENMARK below SUNPHARMA and MAXHEALTH on both quality and relative valuation within the sector.
Open questions
- ?Does the falling debt trend reflect a deliberate de-leveraging plan, and over what horizon does management project D/E to reach sector-comparable levels?
- ?How much of the 15.8% five-year earnings growth is attributable to operational improvement versus financial restructuring or one-time items, given that FCF was positive in only 2 of the tracked years?
- ?The forward PE of 29.1 versus trailing PE of 61.7 implies a near-doubling of earnings — what specific revenue or margin drivers are expected to produce that step-change?
- ?Given that 4 of 5 sector peers have missing ROE data and 1-year price change data is unavailable for all peers, how does GLENMARK's risk-adjusted quality profile compare to the broader pharma universe beyond this peer set?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| GLENMARK | Glenmark Pharmaceuticals Ltd.You're viewing | 61.7 | — | 41 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹2,340.60
SMA 50
₹2,226.57
SMA 200
₹2,040.91
RSI (14)
55.4 (neutral)
From 52w high
-5.4%
1Y return
+69.8%
3M return
+19.5%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 12.78 is significantly elevated for a pharma company; peer D/E for Cipla and Dr. Reddys are well below 1.0, pointing to a structural leverage differential that is material to solvency assessment.
- highROE is unavailable for the current period and was above 15% in 0 of the tracked years; persistence consistency score of 20 out of 100 reflects weak capital efficiency history across the measurement window.
- mediumFree cash flow was positive in only 2 of the tracked years, meaning the business has consumed cash in most periods despite 5-year earnings growth of 15.8% and revenue growth of 15.1%.
- mediumTrailing PE of 61.7 ranks 4th of 6 sector peers; quality score of 41 also ranks 4th of 6, below MAXHEALTH (54) and SUNPHARMA (50), placing GLENMARK in the lower half of the sector on combined valuation and quality.
Cross-section contradictions
- Stock is up 69.8% over 1 year and trades above both the 50-DMA (₹2,226) and 200-DMA (₹2,041) with RSI at 55, yet profit margin stands at 6.45% and FCF was positive in only 2 of tracked years — strong price appreciation is not yet matched by consistent cash generation.
- News sentiment registers 3 positive vs 1 negative over 6 total articles, but the D/E of 12.78 and near-zero ROE history represent structural concerns absent from recent headlines.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 24 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days